Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor) (MIAM)

Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

Study Overview

• Status: Completed
• Conditions: Benign Neuronal Desease
• Intervention / Treatment: Device: cerebral MRI

Detailed Description

Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

However, in order to avoid an invasive surgical procedure to remove the lesion, a certain diagnosis of its benignity is essential. The contribution of advanced techniques in MRI, such as spectroscopy in the characterization of these lesions, has not yet been studied today

• Study Type: Observational
• Enrollment (Actual): 71

Contacts and Locations

Study Locations

• France
  • Pierre-Bénite, France, 69495
    • Centre Hospitalier Lyon Sud
  • Saint-Herblain, France, 44800
    • Hôpital Laënnec
  • Bordeaux
    • Bordeaux, Bordeaux, France, 33076
      • Groupe Hospitalier Pellegrin
  • PARIS
    • Paris, PARIS, France, 75019
      • Fondation Adolphe de Rothschild
  • Rennes
    • Rennes, Rennes, France, 35033
      • CHU Rennes
  • Rouen
    • Rouen, Rouen, France, 76000
      • CHU de Rouen
  • Toulouse
    • Toulouse, Toulouse, France, 31059
      • Hôpital Pierre Paul Riquet, CHU Purpan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patient supported for suspicion of MVNT

Description

Inclusion Criteria:

• Patient over 18 years old
• Suspicion of MVNT on an MRI: it is considered that it will be necessary at least the 2 major criteria associated with at least 1 minor criterion to enter the definition of suspicion of MVNT:

Major criteria:

• Multinodular aspect in cluster
• High FLAIR hypersignal / T2

Minor criteria:

• Absence of mass effect
• Hyposignal T1

• Center of the lesion in hypsignal FLAIR or T1 hypersignal

  • Affiliate or beneficiary of a Social Security scheme
  • Having received informed information about the study and consenting to participate in the study

Exclusion Criteria:

• Patient benefiting from a legal protection measure
• Pregnant or lactating woman
• Contraindication to MRI

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)	ratio of N-Acetylaspartate / Choline on Spectroscopy	1 day
Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)	area under curve of the N-Acetylaspartate Spectroscopie	1 day
Description of a new radiological entity on Spectroscopy : : the MVNT (Multinodular and Vacuolating Neuronal Tumor)	area under curve of choline Spectroscopie	1 day

Collaborators and Investigators

• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Study record dates

Study Major Dates

• Study Start (Actual): December 10, 2019
• Primary Completion (Actual): July 10, 2023
• Study Completion (Actual): July 10, 2025

Study Registration Dates

• First Submitted: June 21, 2019
• First Submitted That Met QC Criteria: September 24, 2019
• First Posted (Actual): September 25, 2019

Study Record Updates

• Last Update Posted (Actual): January 5, 2026
• Last Update Submitted That Met QC Criteria: December 30, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: ALR_2019_4

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No